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Abstract Ubiquitin conjugating enzymes participate in the 
thioester cascade that leads to protein ubiquitination. Although 
Ubc9 is homologous to E2 ubiquitin conjugating enzymes we 
have shown that it is unable to form a thioester with ubiquitin, 
but can form a thioester with the small ubiquitin-like protein 
SUMO. Thus Ubc9 is a S U M O conjugating enzyme rather than 
a ubiquitin conjugating enzyme. Transacetylation of Ubc9 by 
S U M O is not mediated by the E l ubiquitin activating enzyme, 
but by a distinct enzymatic activity. S U M O conjugation to 
target proteins is mediated by a different, but parallel pathway to 
ubiquitination. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Modification of proteins by ubiquitin is the critical step in 
targeting proteins for degradation via the proteasome. The 
first stage in this process is activation of ubiquitin by the 
ubiquitin activating enzyme (El ) . In this A T P dependent re-
action the C-terminus of ubiquitin is first adenylated with 
release of pyrophosphate. This is followed by formation of 
a thioester bond between the side chain of a cysteine residue 
in the same E l and the C-terminal carboxyl group of the 
ubiquitin protein with release of A M P . The next stage in 
this process involves a transacetylation reaction which results 
in ubiquitin forming a thioester bond with a conserved cys-
teine residue in a family of ubiquitin conjugating enzymes 
(E2). Ubiquitin is then transferred from the E2 enzyme to 
the ultimate protein acceptor via an isopeptide linkage with 
the e amino group of a lysine in the target protein. In many 
instances this final step requires the participation of ubiquitin 
protein ligase (E3) which may act either as the ultimate ubiq-
uitin donor or in substrate recognition [1]. Polyubiquitinated 
proteins are bound by the 26S proteasome and processively 
degraded. In some instances protein ubiquitination functions 
not as a signal for degradation, but to alter the properties of 
the linked protein. Thus histone ubiquitination alters chroma-
tin structure [2] while ubiquitination of a plasma membrane 
receptor modifies ligand-stimulated endocytosis [3]. Although 
covalent modification of proteins by ubiquitin is now well 
documented it is also clear that a number of other small 
protein molecules can be linked to target proteins in a similar 
fashion to ubiquitin. The protein U C R P , which contains two 
ubiquitin-like domains is conjugated to a number of intracel-
lular proteins by a series of reactions that are separate from 
ubiquitination [4,5]. Recently a small ubiquitin-like protein 
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variously known as sentrin, G M P 1 , S U M O , UBL1 and 
PIC1 has been found covalently linked to R a n GTPase acti-
vating protein 1 ( R a n G A P l ) and associated with a variety of 
other proteins [6-10]. Covalent modification of R a n G A P l 
appears to be necessary for its interaction with the Ran-
G T P binding protein RanBP2 at the cytoplasmic face of the 
nuclear pore complex [8,11]. Also found in the complex be-
tween S U M O modified R a n G A P l and RanBP2 is a protein 
designated Ubc9 which is homologous to the E2 class of 
ubiquitin conjugating enzymes [11]. In yeast Ubc9 is essential 
for cell cycle progression [12] and mammalian homologues 
have been isolated repeatedly from yeast two hybrid screens 
in association with a wide variety of proteins. However, it has 
not been possible to demonstrate that Ubc9 has the enzymatic 
activities that would be expected of a ubiquitin conjugating 
enzyme. 
Here we demonstrate that while Ubc9 is unable to form a 
thioester with ubiquitin it is capable of forming a thioester 
with S U M O , indicating that Ubc9 is a S U M O conjugating 
enzyme rather than a ubiquitin conjugating enzyme. Further-
more, we show that transacetylation of Ubc9 by S U M O is not 
mediated by the ubiquitin activating enzyme E l , but by a 
distinct enzymatic activity. Thus S U M O is conjugated to its 
target proteins by a distinct, but parallel pathway to ubiqui-
tination. 
2. Materials and methods 
2.1. cDNA cloning 
The yeast two hybrid system [13] was used to screen a human 
cDNA expression library for proteins that interact with N-terminal 
regulatory domain of IKBCX (amino acids 1-74). The pV44ER.LexA 
expression vector was used to generate a fusion of the LexA DNA 
binding domain with the N-terminus of IKBO (1-74). A second vector 
pACT was used to express a fusion of Gal4 activation domain with 
proteins encoded by cDNAs in a library generated from human lym-
phocytes [14]. Interacting species were identified in yeast L40a display-
ing histidine independent growth and P-galactosidase activity. A full 
length Ubch9 cDNA was isolated from this cDNA library. The entire 
open reading frame of 474 nucleotides was amplified by polymerase 
chain reaction (PCR) using primers (5'-ACAAACGGATCCATG-
TCGGGGATCGCCCTCAGC-3' and 5'-GCCGCGGAATTCTTAT-
GAGGGCGCAAACTTCTTGGC-3') with additional restriction en-
zyme cleavage sites to facilitate insertion into PGEX-2T such that a 
glutathione 5-transferase-Ubch9 fusion protein can be produced in 
Escherichia coli. cDNA from human Jurkat cells was produced by 
reverse transcription of total RNA and the complete open reading 
frame of Ubch5 isolated by PCR amplification with specific primers 
(5'-ACAAACGGATCCATGGCGCTGAAGAGGATTCAG-3' and 
5'-GCGCGGGATCCTTACATTGCATATTTCTGAGTCC-3') and 
inserted into PGEX-2T as described above. A cDNA encoding the 
complete open reading frame of SUMO was obtained by reverse tran-
scription followed by PCR-amplification (5'-GCCGCGGGATCCC-
TAAACTGTTGAATGACC-3' and 5'-ACAAACGGATCCATGT-
CTGACCAGGAGGCCAAA-3') and inserted into PGEX-2T. PCR 
amplification, using a downstream primer containing a stop codon 
after nucleotide 291 of the open reading frame (5'-GCCGAGG-
GATCCCTAACCCCCCGTTTGTTCCTG-3') was used to create a 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / / S 0 0 1 4 - 5 7 9 3 ( 9 7 ) 0 1 3 0 5 - 7 
298 
modified form of SUMO in which the C-terminus of the protein is 
G97. All GST-fusion constructions were used to transform E. coli 
DH5a to ampicillin resistance. Plasmid DNA was isolated and inserts 
sequenced (ABI377) by Alex Houston of the University of St. An-
drews DNA sequencing facility. 
2.2. Expression and purification of recombinant proteins 
GST-Ubch9 and GST-Ubch5 were expressed in E. coli strain DH5a 
and both GST-Sumo constructions were expressed in E. coli strain 
B834. Induction of expression, glutathione agarose affinity chroma-
tography and thrombin cleavage of fusion proteins were as described 
[15]. Both Sumo proteins were further purified over an anionic ex-
change column (FPLC, Mono Q H5/R5) equilibrated with 50 mM 
Tris pH 7.5 and eluted with a 0-1 M KC1 gradient in 50 mM Tris 
pH 7.5. Human El was purified from HeLa cell extracts by covalent 
affinity chromatography on ubiquitin-Sepharose as described [16]. 
Arabidopsis thaliana El was produced in E. coli BL21DE3 using the 
pET expression system [17] and purified by ubiquitin affinity chroma-
tography as described [16]. 
2.3. Iodination of ubiquitin and Sumo 
Human ubiquitin from Sigma, full length SUMO and SUMOi_97 
expressed in E. coli were radiolabeled with carrier-free Na 125I (Amer-
sham) by the chloramine-T method [18]. [125I]Sumo was fully reduced 
by incubation with 100 mM DTT and after removal of the reducing 
agent by passing through a Biogel P6 spin column, free sulphydryl 
groups were acetylated by incubation with 10 mM iodoacetamide. 
After 10 min at room temperature the iodoacetamide was quenched 
by the addition of DTT to 20 mM. 
2.4. Thioester assay 
Formation of thioester adducts between recombinant E2s (GST-
Ubch5 and Ubch9) and ubiquitin was determined essentially as de-
scribed [19]. Reactions contained the indicated amount of A. thaliana 
El or human El , 1U of inorganic pyrophosphatase (Sigma), 0.5 ug of 
[125I]ubiquitin and recombinant E2s in a final volume of 20 ill of 50 
mM Tris-HCl pH7.6, 10 mM MgCl2, 1 mM ATP. Reactions were 
incubated at 30°C for 10 min and terminated either by boiling for 10 
min in the presence of 2% (w/v) sodium dodecyl sulphate and 4% (v/v) 
2-mercaptoethanol, or by incubating the samples at 30°C for 15 min 
in the same buffer containing 4 M urea instead of 2-mercaptoethanol. 
Samples were subjected to SDS-PAGE (12.5%) and dried gels ana-
lysed by phosphorimaging (Fujix BAS1000, MacBAS software). For-
mation of thioester adducts between recombinant E2s and [125I]Sumo 
was determined using the above procedure with 0.5 ug of [125I]Sumo 
and instead of purified El enzyme, a HeLa cell fraction containing 
Sumo El activity was used. 
2.5. Preparation of HeLa cell fractions 
HeLa cell extracts were prepared and fractionated on Q-Sepharose 
into Fr I and Fr II.1-II.5 as described [20]. 
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Fig. 1. Purification of recombinant proteins. Recombinant proteins 
were purified from E. coli as described in Section 2, subjected to 
SDS-PAGE (12.5%) and stained with Coomassie blue. Lane 1, 1.5 
Ug GST-Ubch9 (44 kDa); lane 2, 1 ug Ubch9 (18 kDa); lane 3, 
1 ug GST-Ubch5 (42 kDa); lane 4, 1.5 ug GST-SUMOj-97 (38 
kDa); lane 5, 1 ug SUMOi_97 (12 kDa); lane 6, 1 ug A. thaliana 
El (123 kDa). The molecular weight of protein markers (M) is 
shown at the left. 
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Fig. 2. Ubch9 is unable to form a thioester with ubiquitin. Assay 
for thioester formation between [125I]ubiquitin and Ubch9 (0.9 ug 
lane 2, 1.8 ug lane 3) or GST-Ubch5 (0.7 ug lane 5, 1.4 ug lane 6) 
in the presence of recombinant A. thaliana El (A) or human El 
from HeLa cells (B). After 10 min at 30°C reactions were termi-
nated and products fractionated by SDS-PAGE under non-reducing 
conditions. 125I radioactivity in the dried gel was detected by phos-
phorimaging. The positions of [125I]ubiquitin and thioester adducts 
with El and E2 proteins are indicated. 
3. Results 
3.1. Ubch9 is unable to form a thioester with ubiquitin 
The NF-KB/Rel proteins are sequestered in the cytoplasm of 
unstimulated cells in association with IKBCC. In response to 
external signals, the N-terminal region of IKBOC is phosphoryl-
ated and ubiquitinated prior to degradation by the protea-
some. Released N F - K B translocates to the nucleus and acti-
vates a large number of responsive genes. To identify proteins 
involved in IKBCC signalling, a yeast two hybrid screen was 
used to isolate human cDNAs encoding proteins that could 
interact with the N-terminal regulatory domain of IKBO: ( 1 -
74). Such a human cDNA was isolated and sequenced to 
reveal an open reading frame of 474 nucleotides encoding a 
158 amino acid protein, identified as the human protein 
Ubch9, which is homologous to ubiquitin conjugating en-
zymes. Although this protein has been repeatedly isolated in 
yeast two hybrid screens evidence that the protein has ubiq-
uitin conjugating activity has not been reported. To character-
ise the enzymatic activity of Ubch9 the protein was expressed 
as a GST fusion in bacteria and purified. A known ubiquitin 
conjugating E2 enzyme, Ubch5 [21], was expressed and puri-
fied in similar fashion (Fig. 1). The ability of purified Ubch9 
and GST-Ubch5 to form a thioester with [125I]ubiquitin in the 
presence of MgATP and recombinant El from A. thaliana 
was analysed by SDS-PAGE under non-reducing conditions. 
While a thioester was formed between GST-Ubch5 and 
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Fig. 3. Detection of a SUMO activating enzyme that transacetylates Ubch9. Unfractionated extract from HeLa cells (Total) or extract fraction-
ated by Q-Sepharose chromatography (fractions I, II. 1, II.2, II.3, II.4, II.5), was assayed for the ability to form thioester adducts with 
[125I]SUMO either alone (—) or in the presence of 1 |Xg Ubch9 (+). ATP was omitted from the lane marked with an asterisk and control lanes 
(A.mix) did not contain any HeLa extract fraction. Reactions products were analysed as described in the legend to Fig. 2. 
[125I]ubiquitin none could be detected using Ubch9 (Fig. 2A). 
To rule out the possibility that this result was a consequence 
of incompatibility between plant E l and human E2 enzymes, 
the human E l enzyme was affinity purified from HeLa cells 
and tested in the same assay with identical results (Fig. 2B). 
Thus, under the conditions employed Ubch9 did not display 
ubiquitin conjugating activity. 
3.2. Ubch9 forms a thioester with iodinated Sumo 
Recently a small ubiquitin-like protein known variously as 
U B L 1 , S U M O , Sentrin and PIC1 has been found covalently 
linked to R a n G A P l and associated with Ubc9 [6-11]. We 
therefore investigated whether Ubch9 might be a S U M O con-
jugating enzyme rather than a ubiquitin conjugating enzyme. 
Full length S U M O or a modified form lacking four amino 
acids from the C-terminus, which is thought to be the active 
form of S U M O [6], were produced in bacteria and purified. 
To determine if ubiquitin activating enzyme could activate 
S U M O , human and A. thaliana E l were used in a thioester 
assay with Ubch9 but were unable to promote thioester for-
mation between Ubch9 and S U M O (data not shown), 
al though these E l enzymes were active for the formation of 
a thioester between ubiquitin and GST-Ubch5 (Fig. 2). Thus 
it seemed likely that S U M O activation would require a dis-
tinct E l activity, distinct from that involved in ubiquitin acti-
vation. To explore this possibility a cytoplasmic extract from 
HeLa cells was incubated with [1 2 5I]SUMO in the presence or 
absence of Ubch9. An activity capable of catalysing formation 
of a Ubch9-[1 2 5I]SUMO thioester in an A T P dependent fash-
ion was detected with the 97 amino acid form of S U M O (Fig. 
3) but not with full length S U M O (data not shown). Fraction-
ation of the HeLa extract by anion exchange chromatography 
revealed that the S U M O El activity was eluted with 0.4 and 
0.5 M KC1 (Fig. 3) and was distinct from the ubiquitin E l 
activity which elutes with 0.3 M KC1 (data not shown). An 
apparent background activity detected in the absence of A T P 
could be explained by formation of a disulphide linkage be-
tween C52 in S U M O and Ubch9. This activity was eliminated 
by iodoacetamide mediated acetylation of S U M O . The ability 
of Ubch9 to form a thioester with acetylated [1 2 5I]SUMO in 
the presence of the S U M O E l activity contained in F r II.4 
was determined. In presence of A T P Ubch9 forms a conjugate 
with [1 2 5I]SUMO that is labile to reducing agents, such as 2-
mercaptoethanol (Fig. 4), indicating that the two molecules 
are linked by a thioester bond. Under the same conditions 
GST-Ubch5 was unable to form conjugates with [1 2 5I]SUMO. 
Thus Ubch9 has the properties of a S U M O conjugating en-
zyme that can act in concert with a unique S U M O activating 
enzyme. 
4. Discussion 
Ubch9 was isolated in a yeast two hybrid screen as a pro-
tein that could interact with the N-terminal region of IKBO:. 
As IKBCX undergoes signal induced ubiquitination within the 
N-terminal domain our expectation was that Ubch9 could 
participate in the ubiquitination of IKBa. Using an in vitro 
system for the phosphorylation and ubiquitination of IKBCC 
[20,22] we were unable to demonstrate a role for Ubch9 
(data not shown). Fur thermore Ubch9 was unable to form a 
thioester with ubiquitin, in the presence of the E l ubiquitin 
activating enzyme, under conditions where this activity could 
be clearly demonstrated with Ubch5 (Fig. 2). 
As it has been reported [9] that the ubiquitin-like protein 
S U M O is found in complexes containing Ubc9 it has been 
suggested that Ubc9 might be involved in S U M O conjugation 
rather than ubiquitination [11]. Here we demonstrate that this 
is indeed the case as Ubch9 can form a thioester with S U M O 
(Figs. 3 and 4) provided that an, as yet, unidentified S U M O 
activating enzyme is present. A possible candidate for such an 
activity is the yeast protein Uba2p which is homologous to 
U b a l , the Saccharomyces cerevisiae E l ubiquitin activating 
enzyme. The UBA2 gene is essential for viability in yeast 
and overexpression of the UBA1 gene does not complement 
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Fig. 4. Ubch9 is a SUMO conjugating enzyme. Ubch9 (1 ug) and 
GST-Ubch5 (1 u.g) were assayed for their ability to be transacetyl-
ated by [125I]SUMO (treated with iodoacetamide) in the presence of 
the SUMO activating enzyme present in HeLa fraction II.4. Assays 
were conducted either in the absence (—) or presence (+) of ATP 
and reaction products analysed as described in the legend to Fig. 2. 
The indicated samples (+SH) were analysed under reducing condi-
tions after treatment with 2-mercaptoethanol. 
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this defect. Like U b a l , Uba2p contains an essential cysteine 
but is unable to activate or form a thioester with ubiquitin 
[23]. It seems likely that S U M O conjugation is carried out by 
a series of transacetylation reactions that is similar but distinct 
from the ubiquitination pathway. Others have reported an 
interaction between Ubch9 and IKBO: in yeast [24] and inter-
preted this as an involvement in IKBa ubiquitination and 
degradation. Given the inability of Ubch9 to conjugate ubiq-
uitin in vitro it seems unlikely that Ubc9 is involved in IKBOC 
degradation, but a role for S U M O modification in other as-
pects of IKBOC metabolism, such as nuclear import [25], cannot 
be ruled out. 
A remaining puzzle is why Ubc9 is isolated from yeast two 
hybrid screens by such a wide variety of proteins. One possi-
ble explanation is that 'bait ' proteins are modified by S U M O 
in yeast and it is the association between S U M O and Ubc9 
that mediates the apparent interaction between Ubc9 and bait 
proteins. 
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